" class="no-js "lang="en-US"> Keith Nurcombe - Medtech Alert
Friday, September 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Keith Nurcombe

Keith Nurcombe

About Keith Nurcombe

Keith has over 25 years’ experience working in healthcare in the UK & EU, working with pharmaceutical & healthcare companies. He also developed a start up business inside O2/Telefonica using tech to support patients with long term conditions away from the hospital environment. Keith is a regular contributor to magazine articles and a speaker at events in the healthcare space as well as being a Non-Executive Director for an NHS Foundation Trust Hospital.

Related Story

News

 Doctorlink Approved for New NHS Procurement Framework | Pharmtech Focus

Doctorlink Approved for NHS Procurement Framework

May 20 2021

Doctorlink has today announced that its Online Consultation and Video Consultation solutions have been approved for NHS England’s Digital […]